{
  "issues": [
    "Patient MAP is 59 mmHg, below the recommended >65 mmHg for safe contrast administration; the current protocol does not require hemodynamic stabilization before CTA.",
    "Renal tool flagged creatinine as a critical fail and noted missing BMI, which is needed to calculate an appropriate weight‑based contrast dose.",
    "Suggested contrast volume (100–150 mL) may be excessive for a patient with eGFR 59 mL/min/1.73 m² and hypotension; a reduced dose or low‑osmolar/iso‑osmolar agent is not mentioned.",
    "Renal safety note uses an atypical metric (contrast‑to‑eGFR ratio <1.1 g/(mL/min)), which is not standard; the usual safety threshold is contrast volume/eGFR <3.7–4.0.",
    "No explicit plan for immediate pre‑procedure renal labs (baseline creatinine) or post‑procedure monitoring beyond a generic statement.",
    "Alternative imaging options (e.g., V/Q scan) are only suggested abstractly; no decision framework based on pre‑test probability (Wells score) is provided."
  ],
  "recommendations": [
    "Stabilize MAP to ≥65 mmHg with cautious fluid resuscitation or vasopressors before any contrast‑enhanced study; defer CTA until hemodynamics are acceptable.",
    "Obtain current weight and calculate BMI; use this to determine a reduced, weight‑based contrast volume (e.g., 50–70 mL of low‑ or iso‑osmolar iodinated contrast) if CTA is still required.",
    "Implement a standardized hydration protocol: 1 mL/kg/h isotonic saline for 12 hours pre‑ and post‑contrast (adjust for heart failure), or at minimum 0.5 mL/kg/h for 1–2 hours before and after if time‑critical.",
    "Consider a split‑dose or low‑rate injection (e.g., 3–4 mL/s) to further reduce nephrotoxic risk.",
    "If the clinical pre‑test probability for PE is low to intermediate, prefer a ventilation‑perfusion scan or bedside transthoracic echocardiography instead of CTA.",
    "Document baseline creatinine and eGFR immediately before contrast; repeat serum creatinine at 24 h and 48 h post‑procedure to detect CIN.",
    "Replace the erroneous contrast‑to‑eGFR safety metric with the widely accepted volume/eGFR ratio (<3.7 mL·min/1.73 m²) for decision‑making.",
    "Include a clear statement that carotid CTA is not indicated for this presentation, and remove it from the protocol selection list."
  ],
  "confidence": 0.86,
  "agent2_confidence": 0.86,
  "timestamp": "2025-09-08T17:20:21.070127Z",
  "tool_outputs": {
    "renal": {
      "tool_id": "renal_tool_v2",
      "checks": [
        {
          "id": "egfr_ckd_epi",
          "units": "ml/min/1.73m2",
          "timestamp": "2025-09-08T17:20:17.345578Z",
          "priority": "critical",
          "value": 59.0,
          "status": "pass",
          "reason": "Low renal risk for contrast."
        },
        {
          "id": "creatinine_mg_dl",
          "units": "mg/dL",
          "timestamp": "2025-09-08T17:20:17.345623Z",
          "priority": "critical",
          "value": 1.7,
          "status": "fail",
          "reason": "Creatinine significantly elevated."
        },
        {
          "id": "bun_creatinine_ratio",
          "timestamp": "2025-09-08T17:20:17.345644Z",
          "priority": "important",
          "value": 20.0,
          "status": "warning",
          "reason": "BUN/Cr ratio suggests prerenal azotemia."
        },
        {
          "id": "potassium_mmol_l",
          "units": "mEq/L",
          "timestamp": "2025-09-08T17:20:17.345678Z",
          "priority": "important",
          "value": 4.6,
          "status": "pass",
          "reason": "Potassium normal."
        }
      ],
      "summary": {
        "overall": "fail",
        "reasons": [
          "Creatinine significantly elevated.",
          "BUN/Cr ratio suggests prerenal azotemia.",
          "Missing BMI or creatinine.",
          "No lab timestamps provided."
        ],
        "confidence": 0.52
      },
      "metadata": {
        "version": "2.0.0",
        "run_ts": "2025-09-08T17:20:17.345791Z"
      }
    }
  },
  "llm_raw": "{\n  \"issues\": [\n    \"Patient MAP is 59 mmHg, below the recommended >65 mmHg for safe contrast administration; the current protocol does not require hemodynamic stabilization before CTA.\",\n    \"Renal tool flagged creatinine as a critical fail and noted missing BMI, which is needed to calculate an appropriate weight‑based contrast dose.\",\n    \"Suggested contrast volume (100–150 mL) may be excessive for a patient with eGFR 59 mL/min/1.73 m² and hypotension; a reduced dose or low‑osmolar/iso‑osmolar agent is not mentioned.\",\n    \"Renal safety note uses an atypical metric (contrast‑to‑eGFR ratio <1.1 g/(mL/min)), which is not standard; the usual safety threshold is contrast volume/eGFR <3.7–4.0.\",\n    \"No explicit plan for immediate pre‑procedure renal labs (baseline creatinine) or post‑procedure monitoring beyond a generic statement.\",\n    \"Alternative imaging options (e.g., V/Q scan) are only suggested abstractly; no decision framework based on pre‑test probability (Wells score) is provided.\"\n  ],\n  \"recommendations\": [\n    \"Stabilize MAP to ≥65 mmHg with cautious fluid resuscitation or vasopressors before any contrast‑enhanced study; defer CTA until hemodynamics are acceptable.\",\n    \"Obtain current weight and calculate BMI; use this to determine a reduced, weight‑based contrast volume (e.g., 50–70 mL of low‑ or iso‑osmolar iodinated contrast) if CTA is still required.\",\n    \"Implement a standardized hydration protocol: 1 mL/kg/h isotonic saline for 12 hours pre‑ and post‑contrast (adjust for heart failure), or at minimum 0.5 mL/kg/h for 1–2 hours before and after if time‑critical.\",\n    \"Consider a split‑dose or low‑rate injection (e.g., 3–4 mL/s) to further reduce nephrotoxic risk.\",\n    \"If the clinical pre‑test probability for PE is low to intermediate, prefer a ventilation‑perfusion scan or bedside transthoracic echocardiography instead of CTA.\",\n    \"Document baseline creatinine and eGFR immediately before contrast; repeat serum creatinine at 24 h and 48 h post‑procedure to detect CIN.\",\n    \"Replace the erroneous contrast‑to‑eGFR safety metric with the widely accepted volume/eGFR ratio (<3.7 mL·min/1.73 m²) for decision‑making.\",\n    \"Include a clear statement that carotid CTA is not indicated for this presentation, and remove it from the protocol selection list.\"\n  ],\n  \"confidence\": 0.86\n}",
  "hallucination_analysis": {
    "statement_assessments": [
      {
        "text": "Patient MAP is 59 mmHg, below the recommended >65 mmHg for safe contrast administration; the current protocol does not require hemodynamic stabilization before CTA.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Renal tool flagged creatinine as a critical fail and noted missing BMI, which is needed to calculate an appropriate weight‑based contrast dose.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Suggested contrast volume (100–150 mL) may be excessive for a patient with eGFR 59 mL/min/1.73 m² and hypotension; a reduced dose or low‑osmolar/iso‑osmolar agent is not mentioned.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact '1.7'"
      },
      {
        "text": "Renal safety note uses an atypical metric (contrast‑to‑eGFR ratio <1.1 g/(mL/min)), which is not standard; the usual safety threshold is contrast volume/eGFR <3.7–4.0.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "No explicit plan for immediate pre‑procedure renal labs (baseline creatinine) or post‑procedure monitoring beyond a generic statement.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Alternative imaging options (e.g., V/Q scan) are only suggested abstractly; no decision framework based on pre‑test probability (Wells score) is provided.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Stabilize MAP to ≥65 mmHg with cautious fluid resuscitation or vasopressors before any contrast‑enhanced study; defer CTA until hemodynamics are acceptable.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Obtain current weight and calculate BMI; use this to determine a reduced, weight‑based contrast volume (e.g., 50–70 mL of low‑ or iso‑osmolar iodinated contrast) if CTA is still required.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Implement a standardized hydration protocol: 1 mL/kg/h isotonic saline for 12 hours pre‑ and post‑contrast (adjust for heart failure), or at minimum 0.5 mL/kg/h for 1–2 hours before and after if time‑critical.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Consider a split‑dose or low‑rate injection (e.g., 3–4 mL/s) to further reduce nephrotoxic risk.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "If the clinical pre‑test probability for PE is low to intermediate, prefer a ventilation‑perfusion scan or bedside transthoracic echocardiography instead of CTA.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Document baseline creatinine and eGFR immediately before contrast; repeat serum creatinine at 24 h and 48 h post‑procedure to detect CIN.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Replace the erroneous contrast‑to‑eGFR safety metric with the widely accepted volume/eGFR ratio (<3.7 mL·min/1.73 m²) for decision‑making.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact '1.7'"
      },
      {
        "text": "Include a clear statement that carotid CTA is not indicated for this presentation, and remove it from the protocol selection list.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      }
    ],
    "counts": {
      "supported": 14,
      "inferred": 0,
      "domain_safe": 0,
      "unverified": 0,
      "contradicted": 0
    },
    "hallucination_score": 0.0,
    "recommendation": {
      "force_revision": false,
      "confidence_reduction": 0.0
    },
    "knowledge_base_summary": {
      "numbers": {
        "subject_id": 20028931.0,
        "age": 72.0,
        "hadm_id": 34567891.0,
        "creatinine_mg_dl": 1.7,
        "bun_mg_dl": 34.0,
        "glucose_mg_dl": 142.0,
        "hemoglobin_g_dl": 10.1,
        "hematocrit_pct": 30.5,
        "platelet_count": 210.0,
        "wbc_count": 12.3,
        "sodium_meq_l": 135.0,
        "potassium_mmol_l": 4.6,
        "chloride_meq_l": 100.0,
        "bicarbonate_meq_l": 21.0,
        "egfr_ckd_epi": 59.0,
        "heart_rate_bpm": 95.0,
        "systolic_bp_mmhg": 82.0,
        "diastolic_bp_mmhg": 48.0,
        "map_mmhg": 59.0,
        "pulse_pressure_mmhg": 34.0,
        "temperature_f": 98.9,
        "spo2_pct": 94.0,
        "respiratory_rate": 22.0,
        "bun_creatinine_ratio": 20.0,
        "hospital_expire_flag": 0.0,
        "data_completeness_pct": 0.95
      },
      "raw_strings_sample": [
        "72",
        "bun_creatinine_ratio",
        "potassium normal.",
        "white",
        "creatinine_mg_dl",
        "210",
        "20",
        "1.7",
        "20.0",
        "34567891"
      ]
    }
  },
  "feedback": {
    "issues": [
      "Patient MAP is 59 mmHg, below the recommended >65 mmHg for safe contrast administration; the current protocol does not require hemodynamic stabilization before CTA.",
      "Renal tool flagged creatinine as a critical fail and noted missing BMI, which is needed to calculate an appropriate weight‑based contrast dose.",
      "Suggested contrast volume (100–150 mL) may be excessive for a patient with eGFR 59 mL/min/1.73 m² and hypotension; a reduced dose or low‑osmolar/iso‑osmolar agent is not mentioned.",
      "Renal safety note uses an atypical metric (contrast‑to‑eGFR ratio <1.1 g/(mL/min)), which is not standard; the usual safety threshold is contrast volume/eGFR <3.7–4.0.",
      "No explicit plan for immediate pre‑procedure renal labs (baseline creatinine) or post‑procedure monitoring beyond a generic statement.",
      "Alternative imaging options (e.g., V/Q scan) are only suggested abstractly; no decision framework based on pre‑test probability (Wells score) is provided."
    ],
    "recommendations": [
      "Stabilize MAP to ≥65 mmHg with cautious fluid resuscitation or vasopressors before any contrast‑enhanced study; defer CTA until hemodynamics are acceptable.",
      "Obtain current weight and calculate BMI; use this to determine a reduced, weight‑based contrast volume (e.g., 50–70 mL of low‑ or iso‑osmolar iodinated contrast) if CTA is still required.",
      "Implement a standardized hydration protocol: 1 mL/kg/h isotonic saline for 12 hours pre‑ and post‑contrast (adjust for heart failure), or at minimum 0.5 mL/kg/h for 1–2 hours before and after if time‑critical.",
      "Consider a split‑dose or low‑rate injection (e.g., 3–4 mL/s) to further reduce nephrotoxic risk.",
      "If the clinical pre‑test probability for PE is low to intermediate, prefer a ventilation‑perfusion scan or bedside transthoracic echocardiography instead of CTA.",
      "Document baseline creatinine and eGFR immediately before contrast; repeat serum creatinine at 24 h and 48 h post‑procedure to detect CIN.",
      "Replace the erroneous contrast‑to‑eGFR safety metric with the widely accepted volume/eGFR ratio (<3.7 mL·min/1.73 m²) for decision‑making.",
      "Include a clear statement that carotid CTA is not indicated for this presentation, and remove it from the protocol selection list."
    ],
    "confidence": 0.86
  }
}